Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCLnow 19# (Sclnow Biotechnology Co., Ltd.)
- Development stage
- Unknown
- Lead developer
- Sclnow Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
SCLnow 19# (also known as 19#iSCLife-CI) is an allogeneic human umbilical cord mesenchymal stem cell (hUC-MSC) therapy developed by Sclnow Biotechnology Co., Ltd. for the treatment of cerebral infarction (ischemic stroke) in the convalescent period. This cell-based biologic therapy utilizes the regenerative and immunomodulatory properties of MSCs to promote neurological recovery. The mechanism of action involves the secretion of paracrine factors that provide neuroprotection, reduce inflammation, and stimulate endogenous tissue repair and angiogenesis. The therapy was evaluated in a randomized, double-blind Phase 1/2 clinical trial (NCT03176498) involving intravenous administration, though the trial status is currently listed as suspended.
- Brand names
- iSCLife-CI
- Other names
- allogeneic human umbilical cord mesenchymal stem cellshUC-MSCsallogeneic umbilical cord mesenchymal stem cells
Beyond the preview
Go deeper on SCLnow 19# (Sclnow Biotechnology Co., Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCLnow 19# (Sclnow Biotechnology Co., Ltd.).